- Home
- UTF vs HRMY Comparison
UTF vs HRMY Comparison
Compare UTF & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTF
- HRMY
- Stock Information
- Founded
- UTF 2004
- HRMY 2017
- Country
- UTF United States
- HRMY United States
- Employees
- UTF N/A
- HRMY N/A
- Industry
- UTF Finance Companies
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- UTF Finance
- HRMY Health Care
- Exchange
- UTF Nasdaq
- HRMY Nasdaq
- Market Cap
- UTF 2.6B
- HRMY 2.1B
- IPO Year
- UTF N/A
- HRMY 2020
- Fundamental
- Price
- UTF $27.08
- HRMY $37.90
- Analyst Decision
- UTF
- HRMY Strong Buy
- Analyst Count
- UTF 0
- HRMY 9
- Target Price
- UTF N/A
- HRMY $55.33
- AVG Volume (30 Days)
- UTF 171.7K
- HRMY 552.9K
- Earning Date
- UTF 01-01-0001
- HRMY 08-05-2025
- Dividend Yield
- UTF 7.19%
- HRMY N/A
- EPS Growth
- UTF N/A
- HRMY 58.41
- EPS
- UTF 2.84
- HRMY 3.10
- Revenue
- UTF $138,636,669.00
- HRMY $772,527,000.00
- Revenue This Year
- UTF N/A
- HRMY $20.45
- Revenue Next Year
- UTF N/A
- HRMY $17.32
- P/E Ratio
- UTF $9.16
- HRMY $12.12
- Revenue Growth
- UTF 19.80
- HRMY 17.74
- 52 Week Low
- UTF $22.05
- HRMY $26.47
- 52 Week High
- UTF $26.53
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- UTF 58.06
- HRMY 66.14
- Support Level
- UTF $26.80
- HRMY $36.08
- Resistance Level
- UTF $27.04
- HRMY $37.46
- Average True Range (ATR)
- UTF 0.20
- HRMY 1.08
- MACD
- UTF -0.01
- HRMY 0.17
- Stochastic Oscillator
- UTF 70.83
- HRMY 97.12
About UTF Cohen & Steers Infrastructure Fund Inc
Cohen & Steers Infrastructure Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is total return with an emphasis on income. It invests majority of its managed assets in securities issued by infrastructure companies, which consists of utilities, pipelines, toll roads, airports, railroads, ports, telecommunications companies, and other infrastructure companies, under normal market conditions.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.